Addyi

The positive late-stage results for female arousal drug from Palatin Technologies, Inc. (NYSE: PTN) once again throw light on the underappreciated market of female sexual health. Palatin announced the late-stage study of bremelanotide met its primary endpoint to treat hypoactive sexual desire...

Reuters reported after Monday's market close that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plans on cutting its sales force for Addyi, a treatment aimed at female sexual dysfunction. Reuters noted that an outside sales force handles sales for Addyi, which fell under Valeant's corporate...

Canadian pharmaceutical behemoth Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced on Thursday that it would be acquiring Sprout Pharmaceuticals Inc., the maker of female libido drug Addyi for $1 billion. On Tuesday, Addyi received FDA's approval, becoming the first female libido drug...